Search
for
Sort by
Research 30 of 1000+
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- 1322 Molecular profiling of frontal fibrosing alopecia (FFA) reveals TH1 and JAK-STAT up-regulation with no suppression of hair keratins
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- JAK1 Signaling Is Involved in the Induction of Mechanical Alloknesis in Atopic Dermatitis
- Keratin 6A promotes skin inflammation through JAK1-STAT3 activation in keratinocytes
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- 1359 Hair growth is induced by blockade of macrophage-derived oncostatin M and downstream JAK-STAT5 signaling in hair follicle stem cells
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- Inhibidores de JAK: usos en dermatología. Parte 1: generalidades, aplicaciones en vitíligo y en alopecia areata
- 18883 Androgenetic alopecia pattern hair regrowth in patients with alopecia areata treated with oral JAK inhibitors
- Efficacy of JAK inhibitors in the treatment of alopecia: A case report of 10 patients
- 126 Itch of Dermatomyositis treated with topical JAK inhibitor
- Rapidly progressive alopecia areata totalis in a COVID‐19 patient, unresponsive to tofacitinib
- Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Iron Chelators in the Management of Autoimmune-Induced Alopecia: A Focus on Hypoxia-Inducible Factor 1 Modulation and Hair Restoration
- Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition